💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Congo receives long-awaited mpox vaccine doses

Published 09/05/2024, 08:56 AM
Updated 09/06/2024, 01:16 AM
© Reuters. FILE PHOTO: Doses of Bavarian Nordic's Imvanex vaccine, used to protect against mpox virus, at the Edison municipal vaccination centre in Paris, France July 27, 2022. Alain Jocard/Pool via REUTERS/File Photo

By Ange Kasongo and Justin Makangara

KINSHASA (Reuters) -Democratic Republic of Congo received its first batch of mpox vaccines on Thursday, which health authorities hope will help curb an outbreak that has prompted the U.N. to declare a global public health emergency.

Congo is the epicentre of the outbreak, which has spread to neighbouring countries and elsewhere, but a lack of vaccines in Africa has hampered efforts to stop the spread of the sometimes deadly disease.

A plane carrying doses manufactured by Bavarian Nordic and donated by the European Union touched down in the capital Kinshasa around 13:00 local time (12:00 GMT), Reuters reporters at the airport said.

Congo's health minister, Samuel Roger Kamba Mulamba, told reporters the newly arrived vaccine had already proved its worth in the United States and would be rolled out to adults in Congo.

"We know which provinces are heavily affected, notably Equateur and South Kivu... The idea is to contain the virus as quickly as possible," he added.

This first delivery amounts to 99,000 doses and a further delivery on Saturday will take the total to 200,000 doses, said Laurent Muschel, the head of the EU Health Emergency Preparedness and Response Authority (HERA).

Overall, Europe aims to deliver 566,000 doses to wherever needs are greatest in the region, Muschel told Reuters. "Based on the number of cases, the next country (for deliveries) should be Burundi, but the country's medical agency must authorise it."

The arrival of the vaccine in Congo should start to address a huge inequity that has left African countries with no access to the two shots used in a 2022 global mpox outbreak, while they were widely available in Europe and the United States.

Congo has said it will launch its vaccination campaign on Oct. 8 to allow time for a thorough awareness-raising campaign to overcome mistrust in some communities.

© Reuters. FILE PHOTO: Doses of Bavarian Nordic's Imvanex vaccine, used to protect against mpox virus, at the Edison municipal vaccination centre in Paris, France July 27, 2022. Alain Jocard/Pool via REUTERS/File Photo

Mpox typically causes flu-like symptoms and pus-filled lesions, and can kill. There were 19,710 suspected cases of mpox reported in Congo in the first eight months of this year, according to the health ministry. Of those, 5,041 were confirmed and 655 were fatal.

It spreads through close contact, including sexual contact.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.